scholarly journals Pleural sarcomatoid mesothelioma

2021 ◽  
Author(s):  
Yair Glick
Keyword(s):  
Sarcomatoid Mesothelioma

scholarly journals Blocking the GITR-GITRL pathway to overcome resistance to therapy in sarcomatoid malignant pleural mesothelioma

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Meilin Chan ◽  
Licun Wu ◽  
Zhihong Yun ◽  
Trevor D. McKee ◽  
Michael Cabanero ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Malignant Pleural Mesothelioma ◽  
Neutralizing Antibodies ◽  
Pleural Mesothelioma ◽  
Spheroid Formation ◽  
Resistance To Therapy ◽  
Sarcomatoid Mesothelioma

AbstractMalignant pleural mesothelioma (MPM) is an aggressive neoplasm originating from the pleura. Non-epithelioid (biphasic and sarcomatoid) MPM are particularly resistant to therapy. We investigated the role of the GITR-GITRL pathway in mediating the resistance to therapy. We found that GITR and GITRL expressions were higher in the sarcomatoid cell line (CRL5946) than in non-sarcomatoid cell lines (CRL5915 and CRL5820), and that cisplatin and Cs-137 irradiation increased GITR and GITRL expressions on tumor cells. Transcriptome analysis demonstrated that the GITR-GITRL pathway was promoting tumor growth and inhibiting cell apoptosis. Furthermore, GITR+ and GITRL+ cells demonstrated increased spheroid formation in vitro and in vivo. Using patient derived xenografts (PDXs), we demonstrated that anti-GITR neutralizing antibodies attenuated tumor growth in sarcomatoid PDX mice. Tumor immunostaining demonstrated higher levels of GITR and GITRL expressions in non-epithelioid compared to epithelioid tumors. Among 73 patients uniformly treated with accelerated radiation therapy followed by surgery, the intensity of GITR expression after radiation negatively correlated with survival in non-epithelioid MPM patients. In conclusion, the GITR-GITRL pathway is an important mechanism of autocrine proliferation in sarcomatoid mesothelioma, associated with tumor stemness and resistance to therapy. Blocking the GITR-GITRL pathway could be a new therapeutic target for non-epithelioid mesothelioma.

scholarly journals Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in Immunogenicity

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1761
Author(s):  
Luka Brcic ◽  
Alexander Mathilakathu ◽  
Robert F. H. Walter ◽  
Michael Wessolly ◽  
Elena Mairinger ◽  
...  
Keyword(s):  
Gene Expression ◽  
Antigen Processing ◽  
Checkpoint Inhibitors ◽  
Cytotoxic T Cells ◽  
Asbestos Exposure ◽  
Gene Expression Pattern ◽  
Digital Gene Expression ◽  
Cell Interaction ◽  
Time To Death ◽  
Sarcomatoid Mesothelioma

Malignant pleural mesothelioma (MPM) is an aggressive malignancy associated with asbestos exposure. Median survival ranges from 14 to 20 months after initial diagnosis. As of November 2020, the FDA approved a combination of immune checkpoint inhibitors after promising intermediate results. Nonetheless, responses remain unsatisfying. Adequate patient stratification to improve response rates is still lacking. This retrospective study analyzed formalin fixed paraffin embedded specimens from a cohort of 22 MPM. Twelve of those samples showed sarcomatoid, ten epithelioid differentiation. Complete follow-up, including radiological assessment of response by modRECIST and time to death, was available with reported deaths of all patients. RNA of all samples was isolated and subjected to digital gene expression pattern analysis. Our study revealed a notable difference between epithelioid and sarcomatoid mesothelioma, showing differential gene expression for 304/698 expressed genes. Whereas antigen processing and presentation to resident cytotoxic T cells as well as phagocytosis is highly affected in sarcomatoid mesothelioma, cell–cell interaction via cytokines seems to be of greater importance in epithelioid cases. Our work reveals the specific role of the immune system within the different histologic subtypes of MPM, providing a more detailed background of their immunogenic potential. This is of great interest regarding therapeutic strategies including immunotherapy in mesothelioma.

scholarly journals P2.06-41 Differentiating Sarcomatoid Mesothelioma from Pleomorphic Carcinoma and Chest Wall Sarcoma Using GATA-3/MUC4/BAP1 IHC

2018 ◽  
Vol 13 (10) ◽  
pp. S758-S759
Author(s):  
Y.Z. Zhang ◽  
T. Adefila-Ideozu ◽  
A. Bowman ◽  
A. Januszewski ◽  
S. Popat ◽  
...  
Keyword(s):  
Chest Wall ◽  
Pleomorphic Carcinoma ◽  
Sarcomatoid Mesothelioma

scholarly journals Invasive sarcomatoid mesothelioma resulting in spinal cord compression: case report

2018 ◽  
Vol 4 (2) ◽  
pp. 20170068
Author(s):  
Matthew Farthing ◽  
Thurkaa Shanmugalingam ◽  
Elizabeth Alice Dean ◽  
Dakshinamoorthy Muthukumar
Keyword(s):  
Spinal Cord ◽  
Case Report ◽  
Spinal Cord Compression ◽  
Cord Compression ◽  
Sarcomatoid Mesothelioma

scholarly journals A Case of Peritoneal Sarcomatoid Mesothelioma with Absence of Occupationl Exposure to Asbestos

2019 ◽  
Vol 34 (2) ◽  
pp. 146 ◽  
Author(s):  
Seung Hoon Yoo ◽  
Hee Man Kim ◽  
Jea Kun Park ◽  
Mi Sung Kim ◽  
Sang Yeop Yi
Keyword(s):  
Sarcomatoid Mesothelioma

Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group

2009 ◽  
Vol 133 (8) ◽  
pp. 1317-1331 ◽  
Author(s):  
Aliya N. Husain ◽  
Thomas V. Colby ◽  
Nelson G. Ordóñez ◽  
Thomas Krausz ◽  
Alain Borczuk ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Interest Group ◽  
Malignant Mesothelioma ◽  
Consensus Statement ◽  
Spindle Cell ◽  
Cytologic Diagnosis ◽  
Pathologic Diagnosis ◽  
Practical Guidelines ◽  
Colonic Adenocarcinomas ◽  
Sarcomatoid Mesothelioma

Abstract Context.—Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. Objective.—To develop practical guidelines for the pathologic diagnosis of MM. Data Sources.—A pathology panel was convened at the International Mesothelioma Interest Group biennial meeting (October 2006). Pathologists with an interest in the field also contributed after the meeting. Conclusions.—There was consensus opinion regarding (1) distinguishing benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiating epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the differential diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM. Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels used is dependent on the differential diagnosis and on the antibodies available in a given laboratory. Immunohistochemical panels should contain both positive and negative markers. The International Mesothelioma Interest Group recommends that markers have either sensitivity or specificity greater than 80% for the lesions in question. Interpretation of positivity generally should take into account the localization of the stain (eg, nuclear versus cytoplasmic) and the percentage of cells staining (>10% is suggested for cytoplasmic membranous markers). These guidelines are meant to be a practical reference for the pathologist.

scholarly journals Diagnostic Usefulness of p16/CDKN2A FISH in Distinguishing Between Sarcomatoid Mesothelioma and Fibrous Pleuritis

2013 ◽  
Vol 139 (1) ◽  
pp. 39-46 ◽  
Author(s):  
Di Wu ◽  
Kenzo Hiroshima ◽  
Shinji Matsumoto ◽  
Kazuki Nabeshima ◽  
Toshikazu Yusa ◽  
...  
Keyword(s):  
Diagnostic Usefulness ◽  
Sarcomatoid Mesothelioma

Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study

2003 ◽  
Vol 42 (3) ◽  
pp. 270-279 ◽  
Author(s):  
D R Lucas ◽  
H I Pass ◽  
S K Madan ◽  
N V Adsay ◽  
A Wali ◽  
...  
Keyword(s):  
Immunohistochemical Study ◽  
Sarcomatoid Mesothelioma
Sign in / Sign up

Export Citation Format

Share Document